Comparative Pharmacology
Head-to-head clinical analysis: TRI LO SPRINTEC versus TRI ESTARYLLA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRI LO SPRINTEC versus TRI ESTARYLLA.
TRI LO SPRINTEC vs TRI-ESTARYLLA
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Tri-Lo Sprintec is a combination oral contraceptive containing ethinyl estradiol and norgestimate. It inhibits ovulation by suppressing gonadotropin release (FSH and LH) from the pituitary, increases viscosity of cervical mucus, and alters endometrial receptivity.
Combination hormonal contraceptive containing ethinyl estradiol and drospirenone. Ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation. Drospirenone is a spironolactone analogue with anti-mineralocorticoid and antiandrogenic activity, also suppressing ovulation and increasing cervical mucus viscosity.
Prevention of pregnancy
Prevention of pregnancyTreatment of moderate acne vulgaris in females ≥14 years of age who have no known contraindications to oral contraceptive therapy and have achieved menarche
One tablet (0.035 mg ethinyl estradiol + 0.180/0.215/0.250 mg norgestimate) orally once daily for 28-day cycle: active tablets on days 1-21, placebo on days 22-28.
One tablet (ethinyl estradiol 0.03 mg / norgestimate 0.18-0.215-0.25 mg) orally once daily for 21 days followed by 7 placebo days.
None Documented
None Documented
Ethinyl estradiol: terminal half-life approximately 17 hours. Norelgestromin (active metabolite of norgestimate): terminal half-life approximately 28 hours. Clinical context: Ethinyl estradiol half-life supports once-daily dosing with steady-state reached within 7-14 days; norelgestromin half-life allows for sustained progestogenic effect.
Terminal elimination half-life is 4-6 hours; clinical context: allows twice-daily dosing for stable blood levels.
Ethinyl estradiol is metabolized primarily via CYP3A4; norgestimate is rapidly metabolized to norelgestromin and subsequently to norgestrel, with further metabolism involving CYP3A4 and other CYP enzymes.
Primarily via CYP3A4; ethinyl estradiol also undergoes sulfation. Drospirenone is metabolized via CYP3A4 and to a minor extent via reduction and subsequent glucuronidation.
Renal (approximately 50-60% as metabolites, with about 20% as unchanged ethinyl estradiol glucuronide and 40% as norgestimate metabolites). Fecal (approximately 30-40% as metabolites).
Renal: approximately 60% as unchanged drug and metabolites; Biliary/fecal: approximately 40%, primarily as metabolites.
Ethinyl estradiol: approximately 97-98% bound to albumin, 2% free. Norelgestromin: approximately 99% bound to sex hormone-binding globulin (SHBG) and albumin.
Approximately 70-80% bound to plasma proteins, primarily albumin.
Ethinyl estradiol: Vd approximately 4-5 L/kg. Norelgestromin: Vd approximately 3-4 L/kg. Clinical meaning: indicates extensive distribution into tissues, not primarily confined to plasma volume.
Approximately 0.5-0.7 L/kg; clinical meaning: moderate distribution into total body water, with limited tissue penetration.
Oral: ethinyl estradiol bioavailability approximately 45% (first-pass effect); norgestimate prodrug converted to norelgestromin with systemic bioavailability of approximately 63%.
Oral: approximately 90% due to minimal first-pass metabolism.
No specific dosing adjustment required for renal impairment. Use caution in severe renal impairment due to potential fluid retention.
No dose adjustment required in mild-to-moderate renal impairment; contraindicated in severe renal disease due to potential fluid retention and hyperkalemia.
Contraindicated in severe hepatic disease or hepatocellular carcinoma. For mild to moderate hepatic impairment (Child-Pugh A or B), use alternative contraception; no established dosing guidelines.
Contraindicated in Child-Pugh class C (severe hepatic impairment); use with caution in Child-Pugh class A or B, with monitoring for signs of hepatotoxicity.
Not indicated for use before menarche. Post-menarche: same dosing as adults (one tablet daily). Safety and efficacy established in females of reproductive age.
Post-menarche only: same as adult dosing (one tablet daily); not indicated for pre-menarche use.
Not indicated for postmenopausal women; no geriatric dosing established.
Not indicated for postmenopausal use; higher risk of thromboembolism and cardiovascular events in women over 35 who smoke; consider non-hormonal contraceptives.
Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive use. This risk increases with age and with heavy smoking (≥15 cigarettes per day) and is quite marked in women over 35 years of age. Women who use combination oral contraceptives should be strongly advised not to smoke.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptives. Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use this product.
["Increased risk of thromboembolic disorders (e.g., venous thromboembolism, stroke, myocardial infarction)","Cigarette smoking increases risk of serious cardiovascular events","Increased risk of hepatic neoplasia (benign and malignant)","Elevated blood pressure","Gallbladder disease","Carbohydrate and lipid metabolic effects"]
["Thrombotic disorders (including venous thromboembolism and arterial thromboembolism)","Liver disease (including hepatic adenoma, liver tumors)","Hypertension","Gallbladder disease","Carbohydrate and lipid metabolism effects","Headache/migraine","Menstrual irregularities and amenorrhea","Depression","Cervical cancer","Hereditary angioedema","Chloasma","Hepatitis C treatment interaction with ombitasvir/paritaprevir/ritonavir and dasabuvir"]
["Known or suspected pregnancy","Current or history of thrombophlebitis or thromboembolic disorders","Cerebrovascular or coronary artery disease","Known or suspected breast cancer or other estrogen-sensitive neoplasia","Undiagnosed abnormal uterine bleeding","Benign or malignant liver tumor or active liver disease","Hypersensitivity to any component","Use of hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir with or without dasabuvir"]
["Hypersensitivity to any component","Thrombophlebitis or thromboembolic disorders","Cerebrovascular or coronary artery disease","Known or suspected breast cancer or other estrogen-dependent neoplasia","Undiagnosed abnormal genital bleeding","Known or suspected pregnancy","Benign or malignant liver tumor or active liver disease","Uncontrolled hypertension","Diabetes with vascular involvement","Migraine with aura (age ≥35)","Renal impairment (GFR <30 mL/min/1.73 m² or history of kidney disease)","Adrenal insufficiency","Cigarette smoking in women over 35","Use of hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir with or without dasabuvir"]
Data Pending Review
Data Pending Review
No significant food interactions. Grapefruit may slightly alter estrogen metabolism but clinically not significant. Maintain consistent dietary habits if constipating.
No significant food interactions. Grapefruit juice may slightly increase estrogen levels but not clinically relevant. Avoid excessive alcohol consumption as it may impair liver function. The pill can be taken with or without food. Taking with food may reduce nausea.
FDA Category X. Use contraindicated in pregnancy due to risk of congenital anomalies, particularly cardiovascular and limb defects, from exposure during first trimester. Second and third trimester exposure associated with potential for fetal harm, including androgenization of female fetuses and liver adenoma. Discontinue promptly if pregnancy occurs.
First trimester: Use not recommended due to risk of cardiovascular and neural tube defects. Second and third trimesters: Fetal exposure to estrogens and progestins may cause genitourinary tract abnormalities, but risk is low. Overall: Pregnancy contraindicated.
Enters breast milk in small amounts (M/P ratio not established). May reduce milk production and quality. Use caution in nursing mothers, especially during early postpartum period. Consider alternative contraception until weaning.
Not recommended during breastfeeding. Small amount of ethinyl estradiol and levonorgestrel/ethinyl estradiol pass into milk. M/P ratio not well established. May reduce milk production and quality.
Contraindicated in pregnancy; no dose adjustments recommended as use is precluded. If inadvertently used, discontinue immediately.
Not applicable as contraindicated in pregnancy. No dose adjustments recommended because use is contraindicated.
Category C
Category C
Tri-Lo Sprintec is a triphasic oral contraceptive with ethinyl estradiol and norgestimate. Monitor for thromboembolic events, especially in smokers over 35. Advise use of backup contraception if vomiting/diarrhea occurs. CYP3A4 inducers may reduce efficacy.
Tri-Estarylla is a combined oral contraceptive containing ethinyl estradiol and norgestimate. It is a triphasic pill with varying hormone doses throughout the cycle. Use for contraception. Monitor for thromboembolic events, especially in smokers over 35. Counsel on missed pill management: if one pill missed, take as soon as remembered; if two or more missed, use backup contraception. May reduce menstrual cramps and acne. Caution in patients with migraine with aura, hypertension, or history of DVT.
Take one tablet daily at the same time; missed doses increase pregnancy risk.Use backup contraception for 7 days after missing 2 or more pills.Report symptoms of blood clots: leg pain/swelling, chest pain, sudden shortness of breath.Avoid smoking while on this medication, especially if over 35.May cause irregular bleeding initially; contact provider if persistent.
Take one pill daily at the same time, preferably after an evening meal to reduce nausea.If you miss one pill, take it as soon as you remember, even if that means taking two pills in one day.If you miss two or more pills, use a backup contraceptive method (e.g., condoms) for the next 7 days.Common side effects include nausea, breast tenderness, breakthrough bleeding, and mood changes; these often improve after 2-3 cycles.Do not smoke while taking this medication, especially if you are over 35, as it increases risk of blood clots.Seek medical attention for signs of blood clot: leg pain/swelling, sudden chest pain, shortness of breath, or severe headache.This medication does not protect against HIV or other sexually transmitted infections.